Windlas Biotech Limited IPO

Windlas Biotech Limited is one of the market leaders in the pharmaceutical formulations CDMO space. The company has a diverse product line-up and an impressive client base.

The platform offers a variety of learning courses to students of classes I - XII. In addition, Byju's also offers online courses to aspirants of competitive and entrance examinations. Accordingly, Byju’s has occupied a large market share and emerged as one of the pioneers in online education over the years.

Windlas Biotech Limited IPO Objectives

- Purchase equipment that will help to expand the company’s Dehradun Plant IV
- Fund incremental working capital needs
- Pre-payment and/or repayment of the company's borrowings
- Address general corporate purposes

Windlas Biotech Limited IPO - Details

This upcoming IPO will comprise new issues worth Rs. 165 crores and offer for sale (OFS) of 5.14 million shares. Here are other vital IPO details.

Opening Date

To be updated

Closing Date

To be updated

Price Band

To be updated

per equity share

Issue Size

₹ To be updated

Face Value

₹ To be updated

per equity share

Market Lot

To be updated

Opening Date

To be updated

Closing Date

To be updated

Price Band

To be updated

per equity share

Issue Size

₹ To be updated

Face Value

₹ To be updated

per equity share

Market Lot

To be updated

Listing at NSE, BSE

Windlas Biotech Limited IPO Important Dates

IPO Open Date 4 August 2021
IPO Close Date 6 August 2021
Basis Of Allotment Date 11 August 2021
Initiation Of Refunds 12 August 2021
Credit Of Shares To
Demat ACcount
13 August 2021
IPO Listing Date 17 August 2021
UPI Mandate Expiry Date Yet to be announced

Why Should You Invest in Windlas Biotech Limited IPO?

Besides being a domestic leader in the CDMO segment, Windlas Biotech boasts an innovative product portfolio comprising complex generic products. Also, its team of experienced and proficient managers and promoters continue to act as its moat.

Moreover, its impressive earnings make for sustained growth and revenue generation. Regardless, investors willing to subscribe to Windlas Biotech Limited IPO shares should gather information about the same in detail. Also, they should keep an eye on the latest development of this upcoming IPO to understand its prospects better.

Financial highlights

Financial year Total Revenue in Crores Total Assets in Crores Profit After Tax in Crores
FY2020-21 (as of December 2020) Rs. 3,230.94 Rs. 3,158.83 Rs. 96.74
FY2019-20 Rs. 3,313.39 Rs. 3,384.88 Rs. 162.13
FY2018-19 Rs. 3,115.25 Rs. 2,981.80 Rs. 638.22
FY2017-18 Rs. 3,565.76 Rs. 2,898.87 Rs. 111.98

How to apply for Windlas Biotech Limited IPO?

You can apply for the Windlas Biotech Limited IPO in these ways:

UPI
Link your bank account to a reliable UPI ID and register it with your Angel One account. Proceed to book Windlas Biotech Limited IPO shares using the ID, confirm the payment on the UPI app, and block the amount for allotment.

Demat Account

1. If you are already a client of Angel One, apply directly for Windlas Biotech Limited IPO, click here.
2. If you’re a new investor Open DEMAT Account for free with Angel One to begin your investment journey.

Windlas Biotech IPO – Company Highlights

Windlas Biotech Limited is one of the top 5 domestic pharmaceutical formulations CDMO companies in the country. The company has 4 active manufacturing facilities based in Uttarakhand. In addition, this company is proactive in selling products in the OTC and trade generics markets.

Other prominent highlights of Windlas Biotech include :

- It extends multiple CDMO services, including product discovery, product development, commercial manufacturing, and licensing.

- Windlas Biotech runs three business verticals, namely CDMO Products and Services, Domestic Trade Generics and Over-the-counter (OTC) market, and Export.

- Its clientele comprises reputed names such as Intas Pharmaceuticals, Sanofi India, Pfizer, and Cadila Healthcare.

- Windlas Biotech’s manufacturing facilities based in Dehradun have an operating capacity of nearly 7,063.83 million tablets/capsules, 61.08 million liquid (bottles), and 54.46 million sachets.

According to reports, the company is also planning to launch a complex generic products category.

Windlas Biotech Limited IPO - SWOT Analysis

strengths

Strengths

  • Product Diversity: Windlas Biotech has a unique portfolio with diverse product offerings. Its range of services and branded products have found application in the OTC and trade generics market. This works in favour of the company's top-line growth.
  • International Presence: Robust exports are one of this company’s key strengths. The international market share has helped Windlas diversify its operations geographically. It also serves as a significant source of revenue.
  • Robust Production Capacity: The high production capacity of this pharmaceutical formulations CDMO manufacturer offers an edge over its competitors.
Weaknesses

Weaknesses

  • Low Investments in R&D: This is a widespread problem with the pharmaceutical industry in the country in general. A more streamlined endeavour could help this company unlock its true potential by staying ahead of the market trends. It can also help align production per market requirements.
Opportunities

Opportunities

  • Growth Prospect: This company’s production venture is mostly based in Uttarakhand. However, the company has ample resources to consider expansion in other states of the country.
Threats

Threats

  • Price Regulation: Drug Price Control Order often limits the company’s potential to generate higher returns. If the company fails to have a sound financial strategy in place, it could falter because of strict pricing norms.
  • Change in Export Laws: Modifications in export regulations and non-tariff barriers could emerge as major roadblocks.
Strenghts Strengths
Weaknesses Weaknesses
Opportunities Opportunities
Threats Threats

Strengths

  • Product Diversity: Windlas Biotech has a unique portfolio with diverse product offerings. Its range of services and branded products have found application in the OTC and trade generics market. This works in favour of the company's top-line growth.
  • International Presence: Robust exports are one of this company’s key strengths. The international market share has helped Windlas diversify its operations geographically. It also serves as a significant source of revenue.
  • Robust Production Capacity: The high production capacity of this pharmaceutical formulations CDMO manufacturer offers an edge over its competitors.

Weaknesses 

  • Low Investments in R&D: This is a widespread problem with the pharmaceutical industry in the country in general. A more streamlined endeavour could help this company unlock its true potential by staying ahead of the market trends. It can also help align production per market requirements.

Opportunities 

  • Growth Prospect: This company’s production venture is mostly based in Uttarakhand. However, the company has ample resources to consider expansion in other states of the country.

Threats 

  • Price Regulation: Drug Price Control Order often limits the company’s potential to generate higher returns. If the company fails to have a sound financial strategy in place, it could falter because of strict pricing norms.
  • Change in Export Laws: Modifications in export regulations and non-tariff barriers could emerge as major roadblocks.

Competitor Analysis: Market Peers

The last couple of years have witnessed a significant surge in demand for biologics and generic medicines. Accordingly, various new CDMO players have mushroomed in the market.

Some of the most popular CDMO companies and market peers of Windlas Biotech include Neuland Laboratories Ltd, Hikal Ltd, Suven Pharmaceuticals Ltd, Laurus Labs Ltd, and Jubilant Life Sciences Ltd.

However, one must note that the CDMO industry, in general, is very consolidated. Therefore, business opportunities in this space are mostly dependent on continued research and expenses to foster growth and expansion.

Windlas Biotech Limited IPO FAQs

What is Windlas Biotech Limited IPO?

Windlas Biotech Limited IPO comprises a new issue of shares amounting to Rs. 165 crores and offer for sale of 5.14 million shares of stakeholders and promoters.

When will Windlas Biotech Limited IPO open for subscription?

The IPO issue will be open to subscription from 4 August 2021. The subscription will close on 6 August 2021.

What is the minimum lot size that retail investors can subscribe to?

Windlas Biotech Limited has not shared any information on subscription.

How will I receive shares?

Windlas Biotech IPO shares will be credited to your Demat account after the allotment process is concluded.

Who are the merchant bankers for Windlas Biotech Limited IPO?

DAM Capital Advisors, SBI Capital Markets Limited, and IIFL Holdings Limited are appointed as the Windlas Biotech IPO merchant bankers.

Who is the registrar for Windlas Biotech Limited IPO?

Link Intime India Private Limited is the registrar for this IPO.

Which categories of investors can participate in Windlas Biotech Limited IPO?

Retail individual investors, qualified institutional buyers, and non-institutional buyers can participate in this IPO.

Who are the promoters of Windlas Biotech Limited IPO?

Ashok Kumar Windlass, AKW WBL Family Pvt Trust, Hitesh Windlass, and Manoj Kumar Windlass are the promoters of Windlas Biotech Limited company.

Enjoy Free Equity

Delivery Trade for Lifetime

Get the link to download the app

Enjoy Lifetime Free Delivery Trade

Download the app now

Or Scan below QR Code

to download App

Open an account